The abstract is read at the publisher; the summary is JClub's.
After California, New Hampshire, Pennsylvania, and South Carolina ended Medicaid weight-management coverage of GLP-1s on January 1, 2026, dispensing fell 85% by 2026 Q1.
- Why it matters: Coverage withdrawal could reduce access to weight-management GLP-1s, but it was unclear how much dispensing would drop and whether other labeled GLP-1 uses would substitute.
- What they did: Using State Drug Utilization Data from 2024 Q1–2026 Q1, dispensing was tracked by FDA-approved indication, and a difference-in-differences model estimated changes in the first quarter after withdrawal.
- The result: In withdrawing states, weight-management prescriptions per 100 enrollee-months dropped from 1.08 in 2025 Q4 to 0.16 in 2026 Q1 (difference-in-differences −0.67, 95% CI −1.21 to −0.18), with no rise in other-indication dispensing beyond +0.23 per 100 enrollee-months.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.